Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma -: Histopathologic and immunohistochemical analysis

被引:77
作者
Poleri, C
Morero, JL
Nieva, B
Vázquez, MF
Rodríguez, C
de Titto, E
Rosenberg, A
机构
[1] Minist Hlth, Pathol Serv, Buenos Aires, DF, Argentina
[2] Minist Hlth, Dept Resp Med, Buenos Aires, DF, Argentina
[3] Minist Hlth, Dept Stat, Buenos Aires, DF, Argentina
[4] Minist Hlth, Dept Thorac Surg, Buenos Aires, DF, Argentina
[5] Minist Hlth, Hosp Rehabil Resp Maria Ferrer & Hlth Promot, Buenos Aires, DF, Argentina
关键词
histopathologic factors; immunohistochemistry; non-small cell lung cancer; prognosis; risk of recurrence; stage I;
D O I
10.1378/chest.123.6.1858
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: To evaluate the prognostic value of histopathologic variables and molecular markers in a group of patients with stage I non-small cell lung cancer (NSCLC). Setting: ''Maria Ferrer" Hospital of Buenos Aires, Argentina. Patients: Pathologic stage IA and IB patients who underwent radical surgery and nonneoadjuvant therapy for NSCLC between January 1985 and December 1999. Measurements and results: Fifty-three patients fulfilling the inclusion criteria were identified. The overall survival was 52.8%, and 28% of patients had recurrent disease. We found significant differences between squamous cell carcinoma (SCC) and adenocarcinoma in mitotic counting (p = 0.001) and lymphatic permeation (p = 0.01). SCCs showed higher proliferation (MIB-1 grades 2 and 3) [p = 0.001], Bcl-2 expression (p = 0.038), and CD44 expression (p = 0.019) than adenocarcinomas. The log-rank test showed that mitosis count, necrosis, MIB-1, and Bcl-2 were predictive factors for relapse. All of them were associated with increased relapse and a shorter time to recurrence. Multivariate analysis using the Cox proportional hazards regression model showed that mitosis count, Bcl-2 expression, and grade 3 of MIB-1 emerged as independent prognostic factors of recurrence. Conclusions: We found that mitosis count and MIB-1 expression had significant value to predict recurrence, reflecting the aggressiveness of high-rate proliferative tumors. We could also show that patients with positive Bcl-2 tumors had a poor outcome, probably related to the uncontrolled cell growth that the expression of Bcl-2 promotes. Our observations are of potential interest for the development of rational postresection treatment strategies based on the estimated risk of recurrence of patients with NSCLC.
引用
收藏
页码:1858 / 1867
页数:10
相关论文
共 30 条
[1]   Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer [J].
Baillie, R ;
Carlile, J ;
Pendleton, N ;
Schor, AM .
JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (02) :116-120
[2]   Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small cell lung cancer [J].
Borner, MM ;
Brousset, P ;
Pfanner-Meyer, B ;
Bacchi, M ;
Vonlanthen, S ;
Hotz, MA ;
Altermatt, HJ ;
Schlaifer, D ;
Reed, JC ;
Betticher, DC .
BRITISH JOURNAL OF CANCER, 1999, 79 (5-6) :952-958
[3]  
CLARKE WM, 1995, MNEMOSYNE, V48, P200
[4]   Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer [J].
Cox, G ;
Jones, JL ;
Andi, A ;
Abrams, KR ;
O'Byrne, KJ .
LUNG CANCER, 2001, 34 (03) :417-426
[5]   A biological staging model for operable non-small cell lung cancer [J].
Cox, G ;
Jones, JL ;
Andi, A ;
Waller, DA ;
O'Byrne, KJ .
THORAX, 2001, 56 (07) :561-566
[6]   A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers [J].
D'Amico, TA ;
Massey, M ;
Herndon, JE ;
Moore, MB ;
Harpole, DH .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 117 (04) :736-742
[7]   Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer [J].
Duarte, IG ;
Bufkin, BL ;
Pennington, MF ;
Gal, AA ;
Cohen, C ;
Kosinski, AS ;
Mansour, KA ;
Miller, JI .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1998, 115 (03) :652-658
[8]   Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients [J].
Fleming, MV ;
Guinee, DG ;
Chu, WS ;
Freedman, AN ;
Caporaso, NE ;
Bennett, WP ;
Colby, TV ;
Tazelaar, H ;
Abbondanzo, SL ;
Jett, J ;
Pairolero, P ;
Trastek, V ;
Liotta, LA ;
Harris, CC ;
Travis, WD .
HUMAN PATHOLOGY, 1998, 29 (01) :60-64
[9]  
Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189
[10]  
HOCKENBERY D, 1995, AM J PATHOL, V146, P16